Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Rastogi

Showing results (21-30 of 85) with videos related to

Pageof 9
Sort By:
Clinical Breast Cancer|February 6, 2010
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancerAndré Robidoux, Aman U Buzdar, Emmanuel Quinaux, et al.
NPJ Breast Cancer|April 26, 2024
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE studyMatthew P Goetz, Irfan Cicin, Laura Testa, et al.
NPJ Breast Cancer|May 21, 2021
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumabPatricia A Ganz, Reena S Cecchini, Louis Fehrenbacher, et al.
Clinical Breast Cancer|June 21, 2011
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupPriya Rastogi, Marc E Buyse, Sandra M Swain, et al.
Breast Cancer Research and Treatment|October 27, 2010
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agentsPamela J Goodwin, Vuk Stambolic, Julie Lemieux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.
Clinical Breast Cancer|July 25, 2008
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupJohn T Hamm, John W Wilson, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2015
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab TrialsCiara C O'Sullivan, Ian Bradbury, Christine Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Edith A Perez, Edward H Romond, Vera J Suman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.
Pageof 9

Showing results (21-30 of 85) with videos related to

Sort By:
Pageof 9
Clinical Breast Cancer|February 6, 2010
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancerAndré Robidoux, Aman U Buzdar, Emmanuel Quinaux, et al.
NPJ Breast Cancer|April 26, 2024
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE studyMatthew P Goetz, Irfan Cicin, Laura Testa, et al.
NPJ Breast Cancer|May 21, 2021
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumabPatricia A Ganz, Reena S Cecchini, Louis Fehrenbacher, et al.
Clinical Breast Cancer|June 21, 2011
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupPriya Rastogi, Marc E Buyse, Sandra M Swain, et al.
Breast Cancer Research and Treatment|October 27, 2010
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agentsPamela J Goodwin, Vuk Stambolic, Julie Lemieux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.
Clinical Breast Cancer|July 25, 2008
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupJohn T Hamm, John W Wilson, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2015
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab TrialsCiara C O'Sullivan, Ian Bradbury, Christine Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Edith A Perez, Edward H Romond, Vera J Suman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.
Pageof 9